{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:46:31Z","timestamp":1793533591028,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,8,10]],"date-time":"2007-08-10T00:00:00Z","timestamp":1186704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2007,9,24]]},"DOI":"10.1007\/s00417-007-0661-y","type":"journal-article","created":{"date-parts":[[2007,8,9]],"date-time":"2007-08-09T13:06:43Z","timestamp":1186664803000},"page":"1727-1730","source":"Crossref","is-referenced-by-count":142,"title":["Combination of laser photocoagulation and intravitreal bevacizumab (Avastin\u00ae) for aggressive zone I retinopathy of prematurity"],"prefix":"10.1007","volume":"245","author":[{"given":"Eun Jee","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Jun","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,8,10]]},"reference":[{"key":"661_CR1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1091-8531(99)70091-1","volume":"3","author":"PG Stenkuller","year":"1999","unstructured":"Stenkuller PG, Du L, Gilbert C et al (1999) Childhood blindness. J AAPOS 3:26\u201332","journal-title":"J AAPOS"},{"key":"661_CR2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/archopht.1990.01070040047029","volume":"108","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1990","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (1990) Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Arch Ophthalmol 108:195\u2013204","journal-title":"Arch Ophthalmol"},{"key":"661_CR3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indication for the treatment of retinopathy of prematurity: results of early treatment for ROP randomized trial. Arch Ophthalmol 121:1684\u20131696","journal-title":"Arch Ophthalmol"},{"key":"661_CR4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","volume":"142","author":"JT Flynn","year":"2006","unstructured":"Flynn JT, Chan-Ling T (2006) Retinopathy of prematurity: Two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol 142:46\u201359","journal-title":"Am J Ophthalmol"},{"key":"661_CR5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1067\/mpa.2000.107904","volume":"4","author":"X Katz","year":"2000","unstructured":"Katz X, Kychenthal A, Dorta P (2000) Zone I retinopathy of prematurity. J AAPOS 4:373\u2013376","journal-title":"J AAPOS"},{"key":"661_CR6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","volume":"81","author":"M O\u2019Keefe","year":"2003","unstructured":"O\u2019Keefe M, Lanigan B, Long VW (2003) Outcome of zone I retinopathy of prematurity. Acta Ophthalmol Scand 81:614\u2013616","journal-title":"Acta Ophthalmol Scand"},{"key":"661_CR7","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","volume":"26","author":"A Kychenthal","year":"2006","unstructured":"Kychenthal A, Dorta P, Katz X (2006) Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 26:S11\u2013S15","journal-title":"Retina"},{"key":"661_CR8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","volume":"92","author":"EA Pierce","year":"1995","unstructured":"Pierce EA, Avery RL, Foley ED et al (1995) Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905\u2013909","journal-title":"Proc Natl Acad Sci USA"},{"key":"661_CR9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487","journal-title":"N Engl J Med"},{"key":"661_CR10","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.1996.01100140419009","volume":"114","author":"EA Pierce","year":"1996","unstructured":"Pierce EA, Foley ED, Smith LE (1996) Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 114:1219\u20131228","journal-title":"Arch Ophthalmol"},{"key":"661_CR11","first-page":"281","volume":"151","author":"N Okamoto","year":"1997","unstructured":"Okamoto N, Tobe T, Hackett SF et al (1997) Animal model. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151:281\u2013291","journal-title":"Am J Pathol"},{"key":"661_CR12","unstructured":"Brady-McCreery KM, McCreery CJ, Sriram V et al (2001) Serum vascular endothelial growth factor and threshold retinopathy of prematurity [abstract]. In: Annual meeting of the American Academy of Ophthalmology; 4th\u20138th November 2001. American Academy of Ophthalmology, vol 3. Abstract, New Orleans, San Francisco, p 113"},{"key":"661_CR13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","volume":"41","author":"SS Lynch","year":"2007","unstructured":"Lynch SS, Cheng CM (2007) Bevacizumab for neovascular ocular diseases. Ann Pharmacother 41:614\u2013625","journal-title":"Ann Pharmacother"},{"key":"661_CR14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"AE Fung","year":"2006","unstructured":"Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344\u20131349","journal-title":"Br J Ophthalmol"},{"key":"661_CR15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1442-9071.2000.00226.x","volume":"28","author":"H Naug","year":"2000","unstructured":"Naug H, Browning J, Gole G, Gobe G (2000) Vitreal macrophages express VEGF165 in oxygen-induced retinopathy. Clin Exp Optom 28:48\u201352","journal-title":"Clin Exp Optom"},{"key":"661_CR16","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1523\/JNEUROSCI.20-18-06781.2000","volume":"15","author":"PA Yourey","year":"2000","unstructured":"Yourey PA, Gohari S, Su JL, Alderson RF (2000) Vascular endothelial cell growth factors promote the in vitro development of rat photoreceptor cells. J Neurosci 15:6781\u20136788","journal-title":"J Neurosci"},{"key":"661_CR17","first-page":"68","volume":"74","author":"T Murata","year":"1996","unstructured":"Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K (1996) The temporal and spatial vascular endothelial growth factor expression in retinal vasculogenesis of rat neonates. Lab Invest 74:68\u201379","journal-title":"Lab Invest"},{"key":"661_CR18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"J Shahar","year":"2006","unstructured":"Shahar J, Avery RL, Heilweil G et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262\u2013269","journal-title":"Retina"},{"key":"661_CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","volume":"26","author":"RP Manzano","year":"2006","unstructured":"Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257\u2013261","journal-title":"Retina"},{"key":"661_CR20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajo.2006.03.058","volume":"142","author":"SJ Bakri","year":"2006","unstructured":"Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ (2006) Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142:162\u2013164","journal-title":"Am J Ophthalmol"},{"key":"661_CR21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","volume":"55","author":"PK Shah","year":"2007","unstructured":"Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K (2007) Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 55:75\u201376","journal-title":"Indian J Ophthalmol"},{"key":"661_CR22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","volume":"38","author":"A Travassos","year":"2007","unstructured":"Travassos A, Teixeira S, Ferreira P et al (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 38:233\u2013237","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"661_CR23","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pearlman J, Pieramici DJ et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695\u20131705","journal-title":"Ophthalmology"},{"key":"661_CR24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.iae.0000233327.68433.02","volume":"26","author":"PM Beer","year":"2006","unstructured":"Beer PM, Wong SJ, Hammad AM, Falk NS, O\u2019Malley MR, Khan S (2006) Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26:871\u2013876","journal-title":"Retina"},{"key":"661_CR25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/archopht.118.5.645","volume":"118","author":"MX Repka","year":"2000","unstructured":"Repka MX, Palmer EA, Tung B (2000) Involution of retinopathy of prematurity. Arch Ophthalmol 118:645\u2013649","journal-title":"Arch Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-007-0661-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-007-0661-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-007-0661-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T19:06:03Z","timestamp":1587841563000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-007-0661-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,10]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,9,24]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1007\/s00417-007-0661-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,10]]}}}